Dynamic path analysis – a useful tool to investigate mediation processes in clinical survival trials

When it comes to clinical survival trials, regulatory restrictions usually require the application of methods that solely utilize baseline covariates and the intention-to-treat principle. Thereby, much potentially useful information is lost, as collection of time-to-event data often goes hand in hand with collection of information on biomarkers and other internal time-dependent covariates. However, there are tools to incorporate information from repeated measurements in a useful manner that can help to shed more light on the underlying treatment mechanisms. We consider dynamic path analysis, a model for mediation analysis in the presence of a time-to-event outcome and time-dependent covariates to investigate direct and indirect effects in a study of different lipid-lowering treatments in patients with previous myocardial infarctions. Further, we address the question whether survival in itself may produce associations between the treatment and the mediator in dynamic path analysis and give an argument that because of linearity of the assumed additive hazard model, this is not the case. We further elaborate on our view that, when studying mediation, we are actually dealing with underlying processes rather than single variables measured only once during the study period. This becomes apparent in results from various models applied to the study of lipid-lowering treatments as well as our additionally conducted simulation study, where we clearly observe that discarding information on repeated measurements can lead to potentially erroneous conclusions.

[1]  O. Aalen A linear regression model for the analysis of life times. , 1989, Statistics in medicine.

[2]  P. Andersen,et al.  Dynamic path analysis in life-course epidemiology. , 2011, American journal of epidemiology.

[3]  Po-Ling Loh,et al.  High-dimensional learning of linear causal networks via inverse covariance estimation , 2013, J. Mach. Learn. Res..

[4]  S. Cole,et al.  Fallibility in estimating direct effects. , 2002, International journal of epidemiology.

[5]  O. Faergeman,et al.  Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[6]  B. Ledergerber,et al.  Analyzing direct and indirect effects of treatment using dynamic path analysis applied to data from the Swiss HIV Cohort Study , 2011, Statistics in medicine.

[7]  Niels Keiding,et al.  Statistical Models Based on Counting Processes , 1993 .

[8]  P. Holland Causal Inference, Path Analysis and Recursive Structural Equations Models. Program Statistics Research, Technical Report No. 88-81. , 1988 .

[9]  O. Aalen,et al.  Survival and Event History Analysis: A Process Point of View , 2008 .

[10]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[11]  Odd O Aalen,et al.  Dynamic Analysis of Recurrent Event Data Using the Additive Hazard Model , 2006, Biometrical journal. Biometrische Zeitschrift.

[12]  J. Robins,et al.  Identifiability and Exchangeability for Direct and Indirect Effects , 1992, Epidemiology.

[13]  R. Emsley,et al.  interventions Mediation and moderation of treatment effects in randomised controlled trials of complex , 2010 .

[14]  Stijn Vansteelandt,et al.  Estimation of direct effects for survival data by using the Aalen additive hazards model , 2011 .

[15]  O. Aalen,et al.  Dynamic path analysis—a new approach to analyzing time-dependent covariates , 2006, Lifetime data analysis.

[16]  Tyler J VanderWeele,et al.  Alternative Assumptions for the Identification of Direct and Indirect Effects , 2011, Epidemiology.

[17]  J. Pearl Causality: Models, Reasoning and Inference , 2000 .

[18]  Stijn Vansteelandt,et al.  On collapsibility and confounding bias in Cox and Aalen regression models , 2013, Lifetime data analysis.

[19]  J. Pearl The Causal Mediation Formula—A Guide to the Assessment of Pathways and Mechanisms , 2012, Prevention Science.

[20]  D. A. Kenny,et al.  The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. , 1986, Journal of personality and social psychology.

[21]  V. Ramjee,et al.  Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math. , 2011, Journal of the American College of Cardiology.

[22]  B. Graubard,et al.  Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.

[23]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[24]  Tyler J VanderWeele,et al.  Causal Mediation Analysis With Survival Data , 2011, Epidemiology.

[25]  P. Renshaw,et al.  [Detection, evaluation, and treatment of high blood cholesterol in adults]. , 2001, Revista panamericana de salud publica = Pan American journal of public health.

[26]  Richard Emsley,et al.  Ian R White interventions Mediation and moderation of treatment effects in randomised controlled trials of complex , 2010 .

[27]  O. D. Duncan Path Analysis: Sociological Examples , 1966, American Journal of Sociology.

[28]  D. Rubin Estimating causal effects of treatments in randomized and nonrandomized studies. , 1974 .

[29]  A. Sniderman,et al.  Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement. , 2011, Journal of clinical lipidology.

[30]  O. Aalen,et al.  Can we believe the DAGs? A comment on the relationship between causal DAGs and mechanisms , 2014, Statistical methods in medical research.

[31]  Odd Aalen,et al.  A Model for Nonparametric Regression Analysis of Counting Processes , 1980 .

[32]  Judea Pearl,et al.  Direct and Indirect Effects , 2001, UAI.

[33]  A. Goldberger STRUCTURAL EQUATION METHODS IN THE SOCIAL SCIENCES , 1972 .

[34]  T. Martinussen,et al.  Dynamic path analysis for event time data: large sample properties and inference , 2010, Lifetime data analysis.

[35]  A. Keech,et al.  Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial: To What Extent Is the Reduction in Coronary Events With Pravastatin Explained by On-Study Lipid Levels? , 2002, Circulation.

[36]  O. Faergeman,et al.  Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study. , 2004, The American journal of cardiology.

[37]  Els Goetghebeur,et al.  Estimation of controlled direct effects , 2008 .

[38]  Richard F MacLehose,et al.  A further critique of the analytic strategy of adjusting for covariates to identify biologic mediation. , 2004, Epidemiologic perspectives & innovations : EP+I.

[39]  Theis Lange,et al.  Direct and Indirect Effects in a Survival Context , 2011, Epidemiology.

[40]  S. Wright The Method of Path Coefficients , 1934 .

[41]  P. Toth Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins: A Meta-analysis , 2012 .